Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should patients with prostate cancer without bone metastases receive sodium clodronate?

Nature Clinical Practice Urology volume 4, pages 584–585 (2007)Cite this article

Access through your institution
Buy or subscribe

boxed-textMason MD et al. (2007) Oral sodium clodronate for nonmetastatic prostate cancer—results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 99: 765–776

Background

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hortobagyi GN et al. (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 1785–1791

    Article  CAS  Google Scholar 

  2. Kyle RA et al. (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25: 2464–2472

    Article  CAS  Google Scholar 

  3. Dearnaley DP et al. (2003) A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 95: 1300–1311

    Article  CAS  Google Scholar 

  4. Saad F et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458–1468

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Murphy, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Surgery, CHUM/Université de Montréal, 1560 Sherbrooke East, Montréal, QC H2L 4M1, Canada fredsaad@videotron.ca

Authors and Affiliations

  1. F Saad is a Professor of Surgery and Urology, and Chief of Urologic Oncology at the University of Montréal Hospital Centre, and University of Montréal Endowed Chair in Prostate Cancer, University of Montréal, Montréal, QC, Canada.,

    Fred Saad

Authors
  1. Fred Saad
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

Fred Saad is a consultant for, is on a speakers' bureau for, and has received grant/research support from Novartis and Sanofi Aventis, and has received grant/research support from Amgen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saad, F. Should patients with prostate cancer without bone metastases receive sodium clodronate?. Nat Rev Urol 4, 584–585 (2007). https://doi.org/10.1038/ncpuro0911

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpuro0911

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing